Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
View Patent ↗Methods of treating a mammal at risk for ischemia-reperfusion injury are provided. The methods comprise administrating an adrenomedullin binding protein-1 (AMBP-1) to the mammal in sufficient amount to reduce the injury. Also provided are methods of treating a mammal at risk for ischemia-reperfusion injury to the bowel. The methods comprise administering adrenomedullin to the mammal in sufficient amount to reduce the injury.
1. A method of treating a mammal at risk for ischemia-reperfusion injury to a kidney, the method comprising administering an amount of adrenomedullin binding protein-1 (AMBP-1) and adrenomedullin to the mammal effective to reduce ischemia-reperfusion injury to a mammalian kidney.
2. The method of claim 1 , wherein the kidney has been transplanted.
3. The method of claim 1 , wherein the mammal is a human.
4. The method of claim 1 , wherein the AMBP-1 is administered at 0.2-200 μg/kg body weight.
5. The method of claim 1 , wherein the adrenomedullin is administered at 0.1-100 μg/kg body weight.
6. The method of claim 1 , wherein the AMBP-1 is administered within 90 minutes of the ischemia.
7. The method of claim 1 , wherein the AMBP-1 is administered before or at the same time as the reperfusion.
8. The method of claim 1 , wherein the AMBP-1 is administered after the reperfusion.
9. The method of claim, 2 , wherein the AMBP-1 and adrenomedullin are administered before the kidney is transplanted.